Concord Drugs Ltd
16 Nov 2026 12:00 AM
Concord Drugs Ltd consolidated sales down 0.91% on year in Q2FY2027,
Concord Drugs Ltd`s net profit slipped by 0.90% to Rs 1.1 crore, while revenue from operations slipped slightly by 0.91% to Rs 20.75 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.76 lakh crore, gaining 6.98%. It has eased by 0.66% over last one week and crept higher by 6.26% in last one month while the market capitalization of Concord Drugs Ltd has slipped by 1.43% and 1.41% in the same period respectively.
Profit before tax (PBT) of Concord Drugs Ltd stood at Rs 1.51 crore in Q2 FY27, jumping 459.26% year-on-year, and declining 1.95% quarter-on-quarter. EBITDA came in at Rs 2 crore, surging by 120.00% YoY and rising 5.68% sequentially.
Total expenses slightly declined by 1.37% to Rs 18.75 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 17.04 crore, posting a minor increase of 3.15% YoY, while employee benefits expense was at Rs 1.56 crore, surging 23.81% YoY.
For FY26, revenue from operations soared by 74.05% to Rs 78.74 crore, while net profit saw a strong growth of 211.76% to Rs 1.06 crore, compared to previous FY. EBITDA surged by 309% to Rs 4.56 crore, and PBT witnessed a strong rise of 113.04% to Rs 1.47 crore compared to previous FY.
The company`s consolidated net cash flow from operating activities stood at Rs 6.77 crore in FY26, as against Rs 3.72 crore in FY25.
Concord Drugs Ltd crashed 17.25% in last one year, underperforming the benchmark BSE Sensex which has slipped by 3.42% during the same period.
Concord Drugs Ltd
13 Nov 2026 12:00 AM
Concord Drugs Ltd consolidated sales down 0.91% on year in Q2FY2027,
Concord Drugs Ltd share price inched up 2.59% to Rs 72.95. The Company`s net profit softened by 0.90% to Rs 1.1 crore, while revenue from operations eased by 0.91% to Rs 20.75 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, easing 6.40%. It has marginally improved by 2.89% over last one week and crept higher by 6.37% in last one month while the market capitalization of Concord Drugs Ltd has improved by 2.52% and 0.08% in the same period respectively.
Profit before tax (PBT) of Concord Drugs Ltd stood at Rs 1.51 crore in Q2 FY27, rallying 459.26% year-on-year, and declining 1.95% quarter-on-quarter. EBITDA came in at Rs 2 crore, jumping 120.00% YoY and gaining 5.68% sequentially.
Total expenses slightly declined by 1.37% to Rs 18.75 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 17.04 crore, growing marginally by 3.15% YoY, while employee benefits expense was at Rs 1.56 crore, surging 23.81% YoY.
For FY26, revenue from operations jumped by 74.05% to Rs 78.74 crore, while net profit jumped 211.76% to Rs 1.06 crore, compared to previous FY. EBITDA witnessed a strong improvement of 309% to Rs 4.56 crore, and PBT soared 113.04% to Rs 1.47 crore compared to previous FY.
The company`s consolidated net cash flow from operating activities stood at Rs 6.77 crore in FY26, as against Rs 3.72 crore in FY25.
Concord Drugs Ltd crashed 17.24% in last one year, underperforming the benchmark BSE Sensex which has eased by 3.03% during the same period.
Concord Drugs Ltd
04 Aug 2026 12:00 AM
Concord Drugs schedules board meeting,
Concord Drugs will hold a meeting of the Board of Directors of the Company on 10 August 2026.
Concord Drugs Ltd
27 May 2026 12:00 AM
Concord Drugs consolidated net profit rises 1225.00% in the March 2026 quarter,
Net profit of Concord Drugs rose 1225.00% to Rs 0.53 crore in the quarter ended March 2026 as against Rs 0.04 crore during the previous quarter ended March 2025. Sales rose 264.68% to Rs 37.89 crore in the quarter ended March 2026 as against Rs 10.39 crore during the previous quarter ended March 2025.For the full year,net profit rose 211.76% to Rs 1.06 crore in the year ended March 2026 as against Rs 0.34 crore during the previous year ended March 2025. Sales rose 74.05% to Rs 78.74 crore in the year ended March 2026 as against Rs 45.24 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales37.8910.39 265 78.7445.24 74 OPM %3.9610.11 -5.789.17 - PBDT1.100.44 150 2.842.12 34 PBT0.750.06 1150 1.470.69 113 NP0.530.04 1225 1.060.34 212 Powered by Capital Market - Live News
Concord Drugs Ltd
19 May 2026 12:00 AM
Concord Drugs to hold board meeting,
Concord Drugs will hold a meeting of the Board of Directors of the Company on 27 May 2026.
Subscribe for our
newsletter
newsletter
HSL Mobile App